司美格鲁肽制剂原研厂家诺和诺德公布了2024年业绩,期内公司实现总营收2904.03亿丹麦克朗(约合421.49亿美元),同比增长26%(固定汇率计算)。其中,司美格鲁肽制剂全年合计收入2018.49亿丹麦克朗,约合292.96亿美元,贡献近70%营收。 另据默沙东公布的帕博利珠单抗2024年销售额294.86亿美元,司美格鲁肽离登顶全球“药王”仅一步之遥,相差不到2亿美元。 在中国市场,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.